Why the study?
Does transdermal glyceryl trinitrate reduce infusion failure and phlebitis in patients receiving peripheral intravenous infusions?
Does transdermal glyceryl trinitrate reduce infusion failure and phlebitis in patients receiving peripheral intravenous infusions?
Transdermal glyceryl trinitrate significantly prolongs the survival of peripheral intravenous infusions and reduces the incidence of superficial phlebitis.
Answers are grounded in this paper and cite their sources.
Supports routine transdermal glyceryl trinitrate with peripheral IVs; confirms efficacy in reducing failure and phlebitis.
Phlebitis is the commonest complication of intravenous infusion. It has been suggested that it is initiated by venoconstriction at the infusion site, hence treatment with a vasodilator may reduce its incidence. We carried out a prospective double-blind controlled study of the effect of transdermal glyceryl trinitrate on the survival of peripheral intravenous infusions in 340 patients. Fifty-five per cent (94 out of 170) of the infusions failed in the control group compared with 19 per cent (33 out of 170) in the treatment group (chi 2 = 45, P less than 0.0005). The commonest cause of infusion failure was superficial phlebitis: 47 per cent in the control group and 17 per cent in the treatment group (chi 2 = 46, P less than 0.0005). The estimated median time of infusion survival was 74 h in the control group compared with 127 h in the treatment group (log rank chi 2 = 143, P less than 0.0001). We conclude that infusion phlebitis is a common problem in hospitalized patients and its incidence can be effectively reduced by transdermal glyceryl trinitrate.
No takes yet. Share an insight, caveat, or question.
Khawaja et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: